Skip to main content

Market Overview

Biogen Rallies On Tecfidera Patent Decision

Share:
Biogen Rallies On Tecfidera Patent Decision

Biogen Inc (NASDAQ: BIIB) shares were trading higher Wednesday following the issuing of a decision by the U.S. Patent and Trademark Office's Patent Trial and Appeal Board on a patent trial challenge by Mylan NV (NASDAQ: MYL) on '514 Tecfidera that was in Biogen's favor.

See Also: 9 Takeaways From The JPMorgan Healthcare Conference

Biogen’s top product is a multiple sclerosis drug, Tecfidera. Mylan had asked the U.S. Patent and Trademark Office to take a look at Biogen’s exclusive hold on Tecfidera until 2028, according to Barron’s.

Biogen shares were trading 24.62% higher at $353.04 at the time of publication, while Mylan shares were up 2.49% at $22.82.

 

Related Articles (BIIB + MYL)

View Comments and Join the Discussion!

Posted-In: Barron'sBiotech News Health Care Legal Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com